Par Pharmaceutical To Acquire Anchen Pharmaceuticals

Enhances Par's R&D Platform
Significantly Increases Current Pipeline
Immediately Accretive in 2011
Conference Call Scheduled for 10:00am ET Today
 
WOODCLIFF LAKE, N.J., Aug. 24, 2011 /PRNewswire via COMTEX/ --

Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products, for $410 million in cash. The transaction is expected to be immediately accretive to non-GAAP earnings in 2011.

Anchen is a profitable, fully-integrated pharmaceutical company with five commercialized products, 27 ANDAs on file with the US FDA, five of which are believed to be first-to-file, and approximately 26 additional products in development. Anchen anticipates launching 8-10 niche generic products over the next two years. Headquartered in Irvine, California, Anchen has 218 employees and over 72,000 sq. ft. of expandable manufacturing and warehouse facilities with state-of-the-art equipment.

Patrick G. LePore, Chairman, CEO and President of Par Pharmaceutical Companies said, "This transaction accelerates the expansion of Par's research and development infrastructure and reinforces our strategy to provide long-term sustainable growth. Anchen has an excellent development track record and robust product pipeline, which, when combined with Par's existing capabilities and pipeline, more than doubles our product opportunities." Mr. LePore continued, "Anchen also shares Par's highly entrepreneurial culture and cost-efficient approach to product development, which should allow for a seamless integration."

The Company intends to finance the transaction with cash on hand and a $350 million term loan.

The acquisition is subject to customary conditions and approvals. Par expects to complete the transaction by the end of the year.

Advisors

Par Pharmaceutical Companies was advised by JKF Advisors LLC, Orrick, Herrington & Sutcliffe LLP, and Arent Fox LLP, PricewaterhouseCoopers LLP, among others. In addition, the Company received a fairness opinion from J.P. Morgan in connection with the transaction.

Anchen Pharmaceuticals was advised by Jefferies & Company and Winston & Strawn LLP.

Conference Call

The Company will host a conference call and webcast to discuss the transaction today at 10:00a.m. Eastern Daylight Time. Access to the live webcast can be made via the Company's website at www.parpharm.com.

Dial-in Information

Domestic: 866-783-2140

International: 857-350-1599

Passcode: 81836190

A replay of the conference call will be available for two weeks approximately one hour after the call.

Replay Information

Domestic: 888-286-8010

International: 617-801-6888

Passcode: 17442854

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.